Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 26;31(2):323–334. doi: 10.3904/kjim.2015.004

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 The Korean Association of Internal Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — The effects of inhibition of renin angiotensin system and TLR on MCP-1 and OPN expression 7 days after UUO. (A) MCP-1 and (B) OPN mRNA expression were increased in UUO kidneys compared with sham-operated kidneys. Aliskiren treatment reduced renal mRNA expression of MCP-1 and OPN in UUO kidneys. Aliskiren-treated TLR2-KO UUO kidneys showed a significant decrease in mRNA expression of MCP-1 and OPN compared with aliskiren-treated WT UUO kidneys. TLR, Toll-like receptor; MCP-1, monocyte chemotactic protein 1; OPN, osteopontin; UUO, unilateral ureteral obstruction; KO, knockout; WT, wild type; S, sham-operated mice (n = 7); UUO, UUO operated mice (n = 8); A-UUO, aliskiren-treated UUO WT mice (n = 8); A-TLR2-KO-UUO, aliskiren-treated TLR2-KO UUO mice (n = 8). ^a,b,cp < 0.05.